Successful Treatment of Acute Uric Acid Nephropathy with Rasburicase in a Primary Central Nervous System Lymphoma Patient Showing a Dramatic Response to Methotrexate-Case Report

• Published in: Journal of clinical medicine Vol. 11; no. 19
• Main Authors: Mouri, Yoshihiro, Natsumeda, Manabu, Okubo, Noritaka, Sato, Taro, Saito, Taiki, Shibuya, Kohei, Yamada, Shiori, On, Jotaro, Tsukamoto, Yoshihiro, Okada, Masayasu, Oishi, Makoto, Eda, Takeyoshi, Murai, Junko, Shimizu, Hiroshi, Kakita, Akiyoshi, Fujii, Yukihiko
• Format: Report
• Language: English
• Published: 22.09.2022
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm11195548

BACKGROUNDPrimary central nervous system lymphomas (PCNSLs) are sensitive to chemotherapy. The standard treatment is high-dose methotrexate (MTX)-based chemotherapy. There are no reports of successful treatment of acute uric acid nephropathy with rasburicase after MTX administration in PCNSLs. CASE PRESENTATIONA 54-year-old man with a history of gout presented with a change in character and cognitive dysfunction. MRI showed a large enhancing mass spanning the bilateral frontal lobes and the right temporal lobe. After endoscopic biopsy, an MTX, procarbazine, and vincristine (MPV) regimen was initiated for the treatment of the PCNSL. After the initiation of chemotherapy, the patient experienced a gout attack, and blood examination revealed acute renal failure (ARF) and hyperuricemia. The considered causes of ARF included MTX toxicity and acute uric acid nephropathy. As the dramatic effect of MTX was observed, treatment was continued despite ARF, most probably due to acute hyperuricemia due to tumor lysis, which was treated in parallel. After an improvement in renal function, MTX was resumed, and rasburicase was initiated to control hyperuricemia. A complete response was obtained after induction chemotherapy. Hyperuricemia was controlled with rasburicase, and renal function was preserved. CONCLUSIONSAcute uric acid nephropathy should be considered when ARF occurs after the initiation of MTX in PCNSLs, especially in newly diagnosed PCNSL patients with large tumors or hyperuricemia.